Mometason Hexal (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells of the nasal mucosa, modifying gene transcription. This reduces the production of inflammatory cytokines and mediators, leading to decreased swelling, mucus production, and overall nasal inflammation.

The prescribed dose is determined by the treating physician based on symptom severity and patient characteristics. Typical regimens involve one or two sprays per nostril once daily, but exact dosing should follow the healthcare provider’s instructions.

Safety data are limited; the product should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant or nursing should discuss use with their healthcare professional before starting therapy.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency glucocorticoid with minimal systemic absorption, offering effective symptom control at low daily doses. Compared with agents such as fluticasone or budesonide, it provides comparable efficacy with a favorable safety profile when used as directed.

Store at room temperature, below 25 °C, in the original packaging. Protect the spray from moisture and direct sunlight, and keep the cap tightly closed when not in use to maintain product stability.

Insert the spray tip into each nostril while the head is upright. One or two sprays per nostril are typically administered once daily, as instructed by the prescriber. The device should be primed before first use and after periods of non‑use according to the package insert.

Rare but serious adverse events can include nasal septum perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal passages. Seek immediate medical attention if any of these symptoms occur.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active nasal infections, recent nasal surgery, or those receiving systemic corticosteroid therapy without medical supervision.